Moderna today downgraded its forecast for sales of its COVID-19 vaccine for 2021 to 5 billion euros, while trying to increase the production of its preparations, leading its share to a dip of 11% in its pre-conference negotiation.
The company said it now expects sales of between $ 15 billion and $ 18 billion from $ 20 billion at its previous estimate. Deliveries are estimated at between 700 million and 800 million installments for the year, compared to the previous forecast of 800 million to 1 billion installments in 2021.
The company cited the longer it takes for international shipments of the drug, which may now postpone some deliveries to 2022, and the temporary impact of expanding its vaccine bottling and packaging capabilities.
Moderna had announced in August that it had “limited capacity” for 2021 and that it had stopped accepting orders for that year. Its production is smaller than that of its competitor Pfizer, which expects sales of its $ 36 billion COVID-19 vaccine in 2021 and $ 29 billion in 2022.
Moderna, however, announced that its sales could be in the range of 17-22 billion dollars next year as it signs agreements with more countries for its vaccines and booster doses.
.
